Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Published:2024-09 Issue:9 Volume:11 Page:e659-e670
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Díez-Campelo María,López-Cadenas Félix,Xicoy Blanca,Lumbreras Eva,González Teresa,del Rey González Mónica,Sánchez-García Joaquín,Coll Jordà Rosa,Slama Bohrane,Hernández-Rivas Jose-Ángel,Thepot Sylvain,Bernal Teresa,Guerci-Bresler Agnès,Bargay Joan,Amigo María Luz,Preudhomme Claude,Fenwarth Laurene,Platzbecker Uwe,Götze Katharina S,Arar Ali,Toribio Sofía,Del Cañizo Consuelo,Hernández-Rivas Jesús María,Fenaux Pierre

Funder

ISCIII

Celgene Corporation

Publisher

Elsevier BV

Reference34 articles.

1. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion;List;Leukemia,2018

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

3. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

4. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

5. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies;Giagounidis;Clin Cancer Res,2006

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SintraREViewed: practice changing, or validation required?;The Lancet Haematology;2024-09